4SC AG Logo

4SC AG

Developing small-molecule epigenetic drugs for high-need cancer indications.

VSC | F

Overview

Corporate Details

ISIN(s):
DE000A3E5C40
LEI:
391200QOKN7LGVP0RQ86
Country:
Germany
Address:
Fraunhoferstr. 22, 82152 Planegg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

4SC AG is a clinical-stage biopharmaceutical company specializing in the development of small-molecule drugs for cancer treatment. The company focuses on oncology indications with high unmet medical needs. Its core research and development strategy targets key epigenetic mechanisms involved in cancer development and progression, with a particular emphasis on histone deacetylase (HDAC) inhibitors. The company's product pipeline comprises drug programs in various stages of clinical development, aiming to offer patients more effective and better-tolerated therapeutic options to improve their quality of life.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-01-16 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 6.3 KB
2025-01-16 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 6.4 KB
2025-01-16 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis zum 30.06.2025
German 6.3 KB
2025-01-16 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis zum 30.06.2025
German 6.4 KB
2024-08-08 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2024 bis zum 30.0…
German 101.6 KB
2023-11-27 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2023 bis zum 31.12.2023
German 6.3 KB
2023-11-27 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2023 bis zum 31.12.2023
German 6.4 KB
2023-11-27 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.4 KB
2023-11-27 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.3 KB
2023-08-10 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2023 bis zum 30.06…
German 100.3 KB
2022-12-20 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
German 6.4 KB
2022-12-20 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
German 6.3 KB
2022-12-20 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
German 6.3 KB
2022-12-20 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
German 6.4 KB
2022-11-30 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2022 bis zum 30.0…
German 174.5 KB

Automate Your Workflow. Get a real-time feed of all 4SC AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for 4SC AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland NOVN
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea 229500
Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark NOVO
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom NFX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary NUTEX
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan 4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland OBSN
ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden ODI
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea 226950
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC

Talk to a Data Expert

Have a question? We'll get back to you promptly.